Exploration of inhibitors targeting KIF18A with ploidy-specific lethality

IF 6.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY Drug Discovery Today Pub Date : 2024-08-19 DOI:10.1016/j.drudis.2024.104142
Qingsong Chen , Xiangyang Le , Qianbin Li , Suyou Liu , Zhuo Chen
{"title":"Exploration of inhibitors targeting KIF18A with ploidy-specific lethality","authors":"Qingsong Chen ,&nbsp;Xiangyang Le ,&nbsp;Qianbin Li ,&nbsp;Suyou Liu ,&nbsp;Zhuo Chen","doi":"10.1016/j.drudis.2024.104142","DOIUrl":null,"url":null,"abstract":"<div><p>Currently, various antimitotic inhibitors applied in tumor therapy. However, these inhibitors exhibit targeted toxicity to some extent. As a motor protein, kinesin family member 18A (KIF18A) is crucial to spindle formation and is associated with tumors exhibiting ploidy-specific characteristics such as chromosomal aneuploidy, whole-genome doubling (WGD), and chromosomal instability (CIN). Differing from traditional antimitotic targets, KIF18A exhibits tumor-specific selectivity. The functional loss or attenuation of KIF18A results in vulnerability of tumor cells with ploidy-specific characteristics, with lesser effects on diploid cells. Research on inhibitors targeting KIF18A with ploidy-specific lethality holds significant importance. This review provides a brief overview of the regulatory mechanisms of the ploidy-specific lethality target KIF18A and the research advancements in its inhibitors, aiming to facilitate the development of KIF18A inhibitors.</p></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"29 10","pages":"Article 104142"},"PeriodicalIF":6.5000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644624002678","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Currently, various antimitotic inhibitors applied in tumor therapy. However, these inhibitors exhibit targeted toxicity to some extent. As a motor protein, kinesin family member 18A (KIF18A) is crucial to spindle formation and is associated with tumors exhibiting ploidy-specific characteristics such as chromosomal aneuploidy, whole-genome doubling (WGD), and chromosomal instability (CIN). Differing from traditional antimitotic targets, KIF18A exhibits tumor-specific selectivity. The functional loss or attenuation of KIF18A results in vulnerability of tumor cells with ploidy-specific characteristics, with lesser effects on diploid cells. Research on inhibitors targeting KIF18A with ploidy-specific lethality holds significant importance. This review provides a brief overview of the regulatory mechanisms of the ploidy-specific lethality target KIF18A and the research advancements in its inhibitors, aiming to facilitate the development of KIF18A inhibitors.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
探索以 KIF18A 为靶点的抑制剂,其致死率具有倍数特异性。
目前,各种抗肿瘤抑制剂被应用于肿瘤治疗。然而,这些抑制剂在一定程度上具有靶向毒性。作为一种运动蛋白,驱动蛋白家族成员 18A(KIF18A)对纺锤体的形成至关重要,它与肿瘤的染色体非整倍体、全基因组加倍和染色体不稳定等特征有关。与传统的抗有丝分裂靶点不同,KIF18A 具有肿瘤特异选择性。KIF18A 的功能缺失或衰减会导致具有倍性特异性的肿瘤细胞变得脆弱,而对二倍体细胞的影响较小。研究具有多倍体特异性致死性的 KIF18A 靶向抑制剂具有重要意义。本综述简要概述了具有倍体特异性致死性靶点KIF18A的调控机制及其抑制剂的研究进展,旨在促进KIF18A抑制剂的开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug Discovery Today
Drug Discovery Today 医学-药学
CiteScore
14.80
自引率
2.70%
发文量
293
审稿时长
6 months
期刊介绍: Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.
期刊最新文献
Efficacy and challenges involving combination therapies in CLL. Strategic partnerships for AI-driven drug discovery: The role of relational dynamics. Antibody-drug conjugates: prospects for the next generation. Improving access to domestic innovative medicines: characteristics and trends of approved drugs in China 2010-2024. Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1